We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
5 Nov 2026 - Baar, Switzerland, 5 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive end […]
Read more2 Nov 2026 - Baar, Switzerland, 2 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional end […]
Read more26 Oct 2026 - Baar, 26 October 2026 – PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that the shareholders approved all […]
Read more16 Oct 2026 - Baar, Switzerland, 16 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive interim […]
Read more13 Oct 2026 - Baar, Switzerland, 13 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional interim […]
Read more2 Oct 2026 - Baar, 2 October 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published the invitation to its extraordinary general […]
Read more31 Aug 2026 - Baar, 31 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that Samsung Peptide AG, a […]
Read more13 Aug 2026 - Baar, 13 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its H1 2026 results, updated […]
Read more20 Jul 2026 - Baar, 20 July 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced Samsung Biologics’ tender offer to […]
Read more